Assessing non‐adjunctive CGM safety at home and in new markets (ANSHIN)
Endocrinology, Diabetes & Metabolism · 2023
DOI: 10.1002/edm2.414 ↗At a glance
Randomisierte kontrollierte Studie in Endocrinology, Diabetes & Metabolism, 2023. Written by Christy Chao and 6 co-authors. Institution: Dexcom, Inc., San Diego, California, USA. Major MEDLINE topics: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Ketoacidosis. Cited 3 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
Continuous glucose monitoring (CGM) can guide treatment for people with type 1 (T1D) and type 2 diabetes (T2D). The ANSHIN study assessed the impact of non‐adjunctive CGM use in adults with diabetes using intensive insulin therapy (IIT). Materials and Methods This single‐arm, prospective, interventional study enrolled adults with T1D or T2D who had not used CGM in the prior 6 months. Participants wore blinded CGMs (Dexcom G6) during a 20‐day run‐in phase, with treatment based on fingerstick glucose values, followed by a 16‐week intervention phase and then a randomized 12‐week extension phase with treatment based on CGM values. The primary outcome was change in HbA1c. Secondary outcomes were CGM metrics. Safety endpoints were the number of severe hypoglycaemic (SH) and diabetic ketoacidosis (DKA) events.
Results
Of the 77 adults enrolled, 63 completed the study. Those enrolled had mean (SD) baseline HbA1c of 9.8% (1.9%), 36% had T1D, and 44% were ≥65 years old. Mean HbA1c decreased by 1.3, 1.0 and 1.0 percentage points for participants with T1D, T2D or age ≥65, respectively ( p < .001 for each). CGM‐based metrics including time in range also improved significantly. SH events decreased from the run‐in period (67.3 per 100 person‐years) to the intervention period (17.0 per 100 person‐years). Three DKA events unrelated to CGM use occurred during the total intervention period.
Conclusions
Non‐adjunctive use of the Dexcom G6 CGM system improved glycaemic control and was safe for adults using IIT.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Dexcom, Inc., San Diego, California, USA.
- Jaeb Center for Health Research, Tampa, Florida, USA.
ORCID profiles: Sarah B Andrade
Cite
APA
Chao, C., Andrade, S. B., Bergford, S., Calhoun, P., Welsh, J. B., Walker, T. C., & ANSHIN Study Group (2023). Assessing non‐adjunctive CGM safety at home and in new markets (ANSHIN). Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.414
Vancouver
Chao C, Andrade SB, Bergford S, Calhoun P, Welsh JB, Walker TC, et al. Assessing non‐adjunctive CGM safety at home and in new markets (ANSHIN). Endocrinology, Diabetes & Metabolism. 2023. doi:10.1002/edm2.414
BibTeX
@article{Chao2023,
author = {Chao, Christy and Andrade, Sarah B and Bergford, Simon and Calhoun, Peter and Welsh, John B and Walker, Tomas C and ANSHIN Study Group, ANSHIN Study Group},
title = {Assessing non‐adjunctive CGM safety at home and in new markets (ANSHIN)},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2023},
doi = {10.1002/edm2.414}
}
EUVIMED